Cell No. : Cell Name
RCB3577 : Yamato-SS
update : 2024/08/14
|
| Comment | Human cell line derived from synovial sarcoma. |
| Comment from the depositor | |
| Terms and conditions | In publishing research results obtained by the use of the BIOLOGICAL RESOURCE, a citation of the literature ref. (Stem Cells 2010;28:1119-1131) designated by the DEPOSITOR is required. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Naka, Norifumi
|
| Originator |
Naka, Norifumi
|
| Year of deposit |
2011
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Gender |
Male
|
| Age at sampling |
30 years
|
| Tissue |
subcutaneous tissue of thigh
|
| Disease name |
Synovial sarcoma (Stage 4)
|
| Metastatic ability |
Yes
|
| Metastatic tissue |
Lung
|
| Classification |
cancer
|
| Year of origin |
2006
|
|
Lifespan |
infinite
|
| Morphology |
other
|
| Cellosaurus(Expasy) |
CVCL_6C44
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Culture medium |
|
DMEM (high glucose, without Sodium pyruvate) + 20% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin + (0.02% EDTA or 0.04% EDTA)
|
Culture information
|
Passage ratio |
|
1 : 6 split
|
| SC frequency |
|
Subculture : 1-2 times/week, Medium Renewal : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma/Acholeplasma |
|
(-)
|
| Animal PCR |
|
OK
|
| STR(human) |
|
OK
|
|
deposit info
|
|
|
lot info
|
| D5S818 |
D13S317 |
D7S820 |
D16S539 |
vWA |
TH01 |
Amelogenin |
TPOX |
CSF1PO |
|
12
|
8,11
|
10,12
|
9,12
|
14,18
|
7,9
|
X,Y
|
8,11
|
10
|
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
9
|
| User's Publication |
5
|
| Reference |
|
15489
Yokoo S, Fujiwara T, Yoshida A, Uotani K, Morita T, Kiyono M, Hasei J, Nakata E, Kunisada T, Iwata S, Yonemoto T, Ueda K, Ozaki T.
Liquid Biopsy Targeting Monocarboxylate Transporter 1 on the Surface Membrane of Tumor-Derived Extracellular Vesicles from Synovial Sarcoma
Cancers (Basel)
2021
13(8):1823
PubMed ID: 33920416
DOI: 10.3390/cancers13081823
|
|
15896
Yasuda N, Takenaka S, Nakai S, Nakai T, Yamada S, Imura Y, Outani H, Hamada K, Yoshikawa H, Naka N.
TAS-115 inhibits PDGFRα/AXL/FLT-3 signaling and suppresses lung metastasis of osteosarcoma
FEBS Open Bio
2020
10(5):767-779
PubMed ID: 32128992
DOI: 10.1002/2211-5463.12827
|
|
16158
Nakai S, Yamada S, Outani H, Nakai T, Yasuda N, Mae H, Imura Y, Wakamatsu T, Tamiya H, Tanaka T, Hamada K, Tani A, Myoui A, Araki N, Ueda T, Yoshikawa H, Takenaka S, Naka N.
Establishment of a novel human CIC-DUX 4 sarcoma cell line, Kitra-SRS, with autocrine IGF-1R activation and metastatic potential to the lungs
Sci Rep
2019
9(1):15812
PubMed ID: 31676869
DOI: 10.1038/s41598-019-52143-3
|
|
15823
Yamada S, Imura Y, Nakai T, Nakai S, Yasuda N, Kaneko K, Outani H, Takenaka S, Hamada K, Myoui A, Araki N, Ueda T, Itoh K, Yoshikawa H, Naka N.
Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma
BMC Cancer
2017
17(1):334
PubMed ID: 28511645
DOI: 10.1186/s12885-017-3324-3
|
|
15501
Yasui H, Imura Y, Outani H, Hamada K, Nakai T, Yamada S, Takenaka S, Sasagawa S, Araki N, Itoh K, Myoui A, Yoshikawa H, Naka N.
Trabectedin is a promising antitumour agent for synovial sarcoma
J Chemother
2016
28(5):417-24
PubMed ID: 27077926
DOI: 10.1080/1120009X.2015.1133013
|
|
15546
Imura Y, Nakai T, Yamada S, Outani H, Takenaka S, Hamada K, Araki N, Itoh K, Yoshikawa H, Naka N.
Functional and therapeutic relevance of hepatocyte growth factor/c-MET signaling in synovial sarcoma
Cancer Sci
2016
107(12):1867-1876
PubMed ID: 27779808
DOI: 10.1111/cas.13092
|
|
16270
Toru Wakamatsu, Norifumi Naka, Satoru Sasagawa, Takaaki Tanaka, Satoshi Takenaka, Nobuhito Araki, Takafumi Ueda, Yasuko Nishizawa, Hideki Yoshikawa, Kazuyuki Itoh
Deflection of vascular endothelial growth factor action by SS18-SSX and composite vascular endothelial growth factor- and chemokine (C-X-C motif) receptor 4-targeted therapy in synovial sarcoma
Cancer Sci
2014
105(9):1124-34
PubMed ID: 24975049
DOI: 10.1111/cas.12469
|
|
15415
Yasui H, Naka N, Imura Y, Outani H, Kaneko K, Hamada K, Sasagawa S, Araki N, Ueda T, Itoh K, Myoui A, Yoshikawa H.
Tailored therapeutic strategies for synovial sarcoma: receptor tyrosine kinase pathway analyses predict sensitivity to the mTOR inhibitor RAD001
Cancer Lett
2014
347(1):114-22
PubMed ID: 24491407
DOI: 10.1016/j.canlet.2014.01.027
|
|
3639
Naka N, Takenaka S, Araki N, Miwa T, Hashimoto N, Yoshioka K, Joyama S, Hamada K, Tsukamoto Y, Tomita Y, Ueda T, Yoshikawa H, Itoh K.
Synovial sarcoma is a stem cell malignancy.
Stem Cells.
2010
28(7):1119-31
PubMed ID: 20518020
DOI: 10.1002/stem.452
|
| User's Publication |
|
19686
Takeuchi M, Nishisho T, Toki S, Kawaguchi S, Tamaki S, Oya T, Uto Y, Katagiri T, Sairyo K.
Blue light induces apoptosis and autophagy by promoting ROS-mediated mitochondr
Cancer Med
2023
12(8):9668-9683
PubMed ID: 36722116
DOI: 10.1002/cam4.5664
|
|
20826
Murayama Y, Kasahara Y, Kubo N, Shin C, Imamura M, Oike N, Ariizumi T, Saitoh A, Baba M, Miyazaki T, Suzuki Y, Ling Y, Okuda S, Mihara K, Ogose A, Kawashima H, Imai C.
NKp44-based chimeric antigen receptor effectively redirects primary T cells against synovial sarcoma.
Transl Oncol
2022
25:101521
PubMed ID: 35998437
DOI: 10.1016/j.tranon.2022.101521
|
|
20170
Yamada H, Takahashi M, Watanuki M, Watanabe M, Hiraide S, Saijo K, Komine K, Ishioka C.
lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma.
Oncol Lett
2021
21(6):455
PubMed ID: 33907565
DOI: 10.3892/ol.2021.12716
|
|
20338
Murayama Y, Kawashima H, Kubo N, Shin C, Kasahara Y, Imamura M, Oike N, Ariizumi T, Saitoh A, Mihara K, Umezu H, Ogose A, Imai C.
Effectiveness of 4-1BB-costimulated HER2-targeted chimeric antigen receptor T cell therapy for synovial sarcoma.
Transl Oncol
2021
14(12):101227
PubMed ID: 34555727
DOI: 10.1016/j.tranon.2021.101227
|
|
13326
Zhou F, Elzi DJ, Jayabal P, Ma X, Chiu YC, Chen Y, Blackman B, Weintraub ST, Houghton PJ, Shiio Y.
GDF6-CD99 Signaling Regulates Src and Ewing Sarcoma Growth.
Cell Rep
2020
PubMed ID: 33147457
DOI: 10.1016/j.celrep.2020.108332
|
Back
Top
CELL BANK Website
